MF研究者総覧

教員活動データベース

Usefulness of blood biomarkers for predicting venous thromboembolism in Japanese patients with cancer

発表形態:
原著論文
主要業績:
主要業績
単著・共著:
共著
発表年月:
2023年03月
DOI:
10.3892/ol.2023.13766
会議属性:
指定なし
査読:
有り
リンク情報:

日本語フィールド

著者:
○Harada Y, Sato A, Nishioka A, Ogusu S, Matsumoto M, Sueoka E, Kawaguchi A, Kimura S, Sueoka-Aragane N
題名:
Usefulness of blood biomarkers for predicting venous thromboembolism in Japanese patients with cancer
発表情報:
Oncol Lett 巻: 25 号: 5 ページ: 180
キーワード:
VTE; biomarkers; neoplasms; prospective studies; risk factors
概要:
Prospective studies on risk factors for the occurrence of venous thromboembolism (VTE) in Asian patients with cancer are limited. Therefore, the present study assessed risk factors for VTE, including multiple blood biomarkers and risk scores consisting of several risk factors, in Japanese patients receiving anticancer drug therapy. In this single-center, prospective, observational study, 200 patients with six types of cancer were enrolled and followed for 1 year to observe the occurrence of symptomatic or asymptomatic VTE. The present study evaluated risk factors, Khorana and Vienna cancer and thrombosis study (CATS) scores at enrollment, and longitudinal data on various blood biomarkers. A Vienna CATS score of ?3 was significantly associated with VTE occurrence (HR, 2.8; 95% CI, 0.9-8.7; P=0.045). In multivariable analysis, there was a significant association between VTE and the presence of pancreatic cancer (HR, 3.2; 95% CI, 1.1-8.8; P=0.028) and high soluble fibrin (HR, 3.7; 95% CI, 1.1-7.8; P=0.036). Covariate analysis using the propensity score also showed a significant association with hemoglobin dichotomized at <100 g/l (HR, 3.9; 95% CI, 1.1-14.0; P=0.034). Longitudinal data indicated that VTE was associated with soluble fibrin baseline values and an increase in D-dimer levels over time. The present results suggested that blood biomarkers are beneficial for predicting the risk of VTE in Japanese patients with cancer. The present study also provided novel evidence for the importance of measuring soluble fibrin in patients with cancer.
抄録:

英語フィールド

Author:
○Harada Y, Sato A, Nishioka A, Ogusu S, Matsumoto M, Sueoka E, Kawaguchi A, Kimura S, Sueoka-Aragane N
Title:
Usefulness of blood biomarkers for predicting venous thromboembolism in Japanese patients with cancer
Announcement information:
Oncol Lett Vol: 25 Issue: 5 Page: 180
Keyword:
VTE; biomarkers; neoplasms; prospective studies; risk factors
An abstract:
Prospective studies on risk factors for the occurrence of venous thromboembolism (VTE) in Asian patients with cancer are limited. Therefore, the present study assessed risk factors for VTE, including multiple blood biomarkers and risk scores consisting of several risk factors, in Japanese patients receiving anticancer drug therapy. In this single-center, prospective, observational study, 200 patients with six types of cancer were enrolled and followed for 1 year to observe the occurrence of symptomatic or asymptomatic VTE. The present study evaluated risk factors, Khorana and Vienna cancer and thrombosis study (CATS) scores at enrollment, and longitudinal data on various blood biomarkers. A Vienna CATS score of ?3 was significantly associated with VTE occurrence (HR, 2.8; 95% CI, 0.9-8.7; P=0.045). In multivariable analysis, there was a significant association between VTE and the presence of pancreatic cancer (HR, 3.2; 95% CI, 1.1-8.8; P=0.028) and high soluble fibrin (HR, 3.7; 95% CI, 1.1-7.8; P=0.036). Covariate analysis using the propensity score also showed a significant association with hemoglobin dichotomized at <100 g/l (HR, 3.9; 95% CI, 1.1-14.0; P=0.034). Longitudinal data indicated that VTE was associated with soluble fibrin baseline values and an increase in D-dimer levels over time. The present results suggested that blood biomarkers are beneficial for predicting the risk of VTE in Japanese patients with cancer. The present study also provided novel evidence for the importance of measuring soluble fibrin in patients with cancer.


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.